Cresset Group has announced that ProMining Therapeutics Ltd has chosen to license sparkV10 for assistance in its hit-to-lead optimization efforts.
sparkV10 is Cresset’s desktop bioisostere software tool which is used by medicinal and computational chemists for drug design.
“sparkV10 is an exciting and powerful way of generating novel and diverse structures. We are delighted that ProMining, an early-stage biopharmaceutical research and development company, has chosen to work with sparkV10 for the development of small molecule drugs,” says Dr David Bardsley, Cresset’s Sales Director.
Dr Boaz Inbal, CTO at ProMining Therapeutics Ltd. says, “We are excited about using sparkV10 for hit-to-lead optimization purposes in our oncology project. We believe that sparkV10 will guide us through several optimization challenges. As a result, we will be able to better understand the behaviour of several chemical groups in the context of our hit scaffold and to test some required replacement hypotheses.”
Dr Bardsley adds, “Cresset’s software works at the meeting point of chemistry and biology, giving chemists a way of understanding their molecules in terms of biological activity. Cresset’s technology and services are providing companies with the right information, wherever they sit in the drug design workflow.”